🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: non-adjuvanted

Found 223 matching trials

Non-specific Response to H1N1 Vaccine

N/A

This is a prospective observational study with recruitment of healthy volun...

Status

Completed

Location

University Clinic of Respiratory and Allergic Diseases

Start Date

2009-11

Trial ID

NCT01178918

Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate

PHASE2

The purpose of this study is to evaluate the immunogenicity and the safety ...

Status

Completed

Location

GSK Investigational Site

Start Date

2006-10-20

Trial ID

NCT00385840

Treatments Being Tested

Influenza Vaccine GSK1247446A FluarixTM

Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)

PHASE2

The purpose of this Phase II follow-up study (to study 810501) is to assess...

Status

Completed

Location

University Hospital, Department of Clinical Pharmacology, General Hospital Vienna

Start Date

2007-09

Trial ID

NCT00530660

Treatments Being Tested

H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

PHASE1

The purpose of this study is to see if two new malaria vaccines called FMP1...

Status

Completed

Location

WRAIR Clinical Trials Center

Start Date

2001-04

Trial ID

NCT01556945

Treatments Being Tested

FMP1/AS02 RTS,S/AS02 AS02 adjuvant alone Malaria challenge

A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers

PHASE2

"Multimeric-001" (M-001) has been recently developed, containing conserved,...

Status

Completed

Location

Hadassah medical center

Start Date

2011-08

Trial ID

NCT01419925

Treatments Being Tested

Two Multimeric-001 administrations followed by TIV One administration of Multimeric-001 followed by TIV One administration of adjuvanted M-001 followed by TIV One administration of placebo followed by TIV

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

PHASE3

The primary purpose of this study is to demonstrate the efficacy of an inve...

Status

Completed

Location

Multiple Locations

Start Date

2007-11

Trial ID

NCT00566345

Treatments Being Tested

Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)Phosphate buffered saline

Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

PHASE1

The purpose of this study is to evaluate the safety and immunogenicity of A...

Status

Completed

Location

University of Maryland School of Medicine - Center for Vaccine Development - Baltimore

Start Date

2019-07-08

Trial ID

NCT04009824

Treatments Being Tested

AGS-v PLUS Vaccine Montanide ISA-51 Adjuvant Alhydrogel® Adjuvant Saline Placebo

Observational Safety Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine

N/A

This is an observational safety study of a prophylactic use of Flu Egg Deri...

Status

Completed

Location

Hospital Garrahan

Start Date

2009-12

Trial ID

NCT01040741

Treatments Being Tested

Non-intervention observational study

Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate

PHASE2

The purpose of this phase IIb study is to demonstrate the consistency of th...

Status

Completed

Location

GSK Investigational Site

Start Date

2006-04-27

Trial ID

NCT00321763

Treatments Being Tested

Candidate Influenza Vaccine GSK1247446A - 3 different formulations Fluarix TM

Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

PHASE1

The objectives of this Phase I/II study are to assess the safety and immuno...

Status

Completed

Location

University of Hong Kong, Queen Mary Hospital

Start Date

2007-07

Trial ID

NCT00517517

Treatments Being Tested

Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation

Previous Next